サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1708005

がん診断の世界市場：産業分析、規模、シェア、成長、動向、予測（2025年～2032年）

Cancer Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 180 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
がん診断の世界市場：産業分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年04月11日
発行: Persistence Market Research
ページ情報: 英文 180 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

主な調査結果

  • がん診断の市場規模：1,378億米ドル（2025年）
  • 予測される市場金額：2,227億米ドル（2032年）
  • 世界市場の成長率：7.1%（2025年～2032年のCAGR）

がん診断市場 - レポート範囲

がん診断には、がんを早期に発見して治療成績と生存率を向上させることを目的とした、幅広いツール、技術、処置が含まれます。この市場には、画像技術、生検技術、腫瘍バイオマーカー、分子診断、ポイントオブケア検査システムなどが含まれます。これらの診断は、病院、病理検査室、専門クリニックなどで、乳がん、肺がん、大腸がん、前立腺がん、子宮頸がん、血液がんなどのさまざまなタイプのがんの検出に利用されています。市場成長の促進要因は、世界のがん罹患率の上昇、早期発見に対する意識の高まり、精密診断と個別化医療の進歩です。

市場成長の促進要因

世界のがん診断市場は複数の要因に後押しされており、特に高齢化、ライフスタイルの変化、環境要因による世界のがん罹患率の増加が挙げられます。先進の診断技術による早期発見は生存率を大幅に向上させ、革新的なソリューションへの需要を促進しています。次世代シーケンシング（NGS）、リキッドバイオプシー、AIを活用した画像診断などの技術的進歩は、がん検出を変革し、低侵襲アプローチを推進しています。がん検診プログラムを支援する政府の取り組み、医療費の増加、腫瘍学におけるコンパニオン診断の採用の拡大が、市場の拡大をさらに刺激しています。

市場抑制要因

堅調な成長が見込まれる一方、がん診断市場は、特に先進の分子検査やゲノム検査における高い診断コストなど、複数の課題に直面しています。中低所得国では診断施設へのアクセスが限られているため、早期発見と治療が阻害されます。さらに、がんの不均一性と遺伝子変異の変化は複雑であるため、継続的な技術革新と臨床的検証が必要となり、開発コストと上市までの期間が増大します。規制上のハードルや償還上の制約も、新しい診断技術の商業的実現可能性に影響を与えます。これらの課題に対処するためには、部門を超えた協力体制と、手頃な価格のスケーラブルな診断プラットフォームへの的を絞った投資が必要です。

市場機会

がん診断市場は、技術革新と診断におけるAIや機械学習の役割の拡大により、大きな成長機会をもたらしています。非侵襲性のリアルタイムがんモニタリングツールとしてリキッドバイオプシーが台頭し、支持を集めています。バイオマーカー探索、ビッグデータアナリティクスの統合、マルチプレックス診断プラットフォームの開発への投資の高まりは、個別化された早期がん診断に新たな道を開きます。さらに、在宅がん検診ツールやモバイル診断への注目が高まることで、特に遠隔地や十分なサービスを受けていない地域におけるアクセシビリティとコンプライアンスが向上する可能性があります。

当レポートでは、世界のがん診断市場について調査し、成長促進要因、動向、機会、課題などの市場力学の詳細な分析を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の概要

  • 市場の範囲と定義
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
    • 主要動向
  • COVID-19の影響の分析
  • 予測要因 - 関連性と影響

第3章 付加価値考察

  • バリューチェーン分析
  • 診断検査の採用/使用の分析
  • がんの有病率と罹患率
  • がん診断における政府の取り組みと資金提供
  • 主要市場企業
  • 規制情勢
  • PESTLE分析
  • ポーターのファイブフォース分析
  • 消費者行動分析

第4章 世界のがん診断市場の見通し

  • 主なハイライト
    • 市場規模と前年比成長
    • 絶対的収益機会
  • 市場規模の分析と予測
    • 市場規模の実績の分析（2019年～2024年）
    • 現在の市場規模の分析と予測（2025年～2032年）
  • 世界のがん診断市場の見通し：診断検査
    • 市場規模の実績の分析：診断検査別（2019年～2024年）
    • 現在の市場規模の分析と予測：診断検査別（2025年～2032年）
    • 市場の魅力分析：診断検査
  • 世界のがん診断市場の見通し：形態
    • 市場規模の実績の分析：形態別（2019年～2024年）
    • 現在の市場規模の分析と予測：形態別（2025年～2032年）
    • 市場の魅力分析：形態
  • 世界のがん診断市場の見通し：用途
    • 市場規模の実績の分析：用途別（2019年～2024年）
    • 現在の市場規模の分析と予測：用途別（2025年～2032年）
    • 市場の魅力分析：用途
  • 世界のがん診断市場の見通し：最終用途
    • 市場規模の実績の分析：最終用途別（2019年～2024年）
    • 現在の市場規模の分析と予測：最終用途別（2025年～2032年）
    • 市場の魅力分析：最終用途

第5章 世界のがん診断市場の見通し地域

  • 市場規模の実績の分析：地域別（2019年～2024年）
  • 現在の市場規模の分析と予測：地域別（2025年～2032年）
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア・オセアニア
    • 中東・アフリカ
  • 市場の魅力分析：地域

第6章 北米のがん診断市場の見通し

第7章 欧州のがん診断市場の見通し

第8章 東アジアのがん診断市場の見通し

第9章 南アジア・オセアニアのがん診断市場の見通し

第10章 ラテンアメリカのがん診断市場の見通し

第11章 中東・アフリカのがん診断市場の見通し

第12章 競合情勢

  • 市場シェア分析（2025年）
  • 市場構造
    • 競合強度マップ：市場別
    • 競合ダッシュボード
  • 企業プロファイル（詳細 - 概要、財務、戦略、近年の発展）
    • F. Hoffmann-La Roche Ltd
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • Illumina Inc.
    • bioMerieux SA
    • Qiagen
    • Siemens Healthineers
    • GE Healthcare
    • Hologic Inc.
    • Agilent Technologies Inc.
    • Becton, Dickinson and Company (BD)
    • Myriad Genetics Inc.
    • AstraZeneca
    • Regeneron
    • Novartis
    • BIO-RAD LABORATORIES
    • CANCER DIAGNOSTICS INC.
    • QUIDEL CORPORATION
    • Koninklijke Philips N.V. (Philips)
    • その他

第13章 付録

目次
Product Code: PMRREP35187

Persistence Market Research has recently released a comprehensive report on the worldwide market for cancer diagnostics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global cancer diagnostics market from 2025 to 2032.

Key Insights:

  • Cancer Diagnostics Market Size (2025E): USD 137.8 Billion
  • Projected Market Value (2032F): USD 222.7 Billion
  • Global Market Growth Rate (CAGR 2025 to 2032): 7.1%

Cancer Diagnostics Market - Report Scope:

Cancer diagnostics encompass a wide range of tools, technologies, and procedures aimed at detecting cancer at early stages to improve treatment outcomes and survival rates. The market includes imaging technologies, biopsy techniques, tumor biomarkers, molecular diagnostics, and point-of-care testing systems. These diagnostics are utilized across hospitals, pathology labs, and specialty clinics to detect various types of cancer, including breast, lung, colorectal, prostate, cervical, and blood cancers. Market growth is driven by the rising global cancer burden, increasing awareness about early detection, and ongoing advancements in precision diagnostics and personalized medicine.

Market Growth Drivers:

The global cancer diagnostics market is propelled by multiple factors, notably the increasing incidence of cancer worldwide due to aging populations, lifestyle changes, and environmental factors. Early detection through advanced diagnostic technologies significantly improves survival rates, driving demand for innovative solutions. Technological advancements such as next-generation sequencing (NGS), liquid biopsy, and AI-powered diagnostic imaging are transforming cancer detection and facilitating minimally invasive approaches. Government initiatives supporting cancer screening programs, rising healthcare expenditure, and the growing adoption of companion diagnostics in oncology further stimulate market expansion.

Market Restraints:

Despite robust growth prospects, the cancer diagnostics market faces several challenges, including high diagnostic costs, especially for advanced molecular and genomic tests. Limited access to diagnostic facilities in low- and middle-income countries impedes early detection and treatment. Additionally, the complexity of cancer heterogeneity and evolving genetic mutations requires continuous innovation and clinical validation, raising development costs and time-to-market. Regulatory hurdles and reimbursement constraints also impact the commercial viability of emerging diagnostic technologies. Addressing these challenges necessitates cross-sector collaboration and targeted investment in affordable, scalable diagnostic platforms.

Market Opportunities:

The cancer diagnostics market presents significant growth opportunities driven by technological innovations and the expanding role of artificial intelligence and machine learning in diagnostics. The emergence of liquid biopsy as a non-invasive, real-time cancer monitoring tool is gaining traction. Growing investments in biomarker discovery, integration of big data analytics, and the development of multiplex diagnostic platforms open new avenues for personalized and early-stage cancer diagnostics. Moreover, increased focus on home-based cancer screening tools and mobile diagnostics can improve accessibility and compliance, especially in remote or underserved areas.

Key Questions Answered in the Report:

  • What are the key factors contributing to the global growth of the cancer diagnostics market?
  • Which diagnostic technologies and cancer types are driving market demand across various regions?
  • How are innovations in molecular diagnostics and AI reshaping the competitive dynamics of the market?
  • Who are the leading players in the cancer diagnostics market, and what strategies are they adopting for market leadership?
  • What are the emerging trends and future opportunities in the global cancer diagnostics landscape?

Competitive Intelligence and Business Strategy:

Leading players in the global cancer diagnostics market, such as F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, and Becton, Dickinson and Company, are actively investing in R&D, strategic collaborations, and acquisitions to enhance their diagnostic portfolios. These companies focus on developing comprehensive cancer detection platforms combining genetic, proteomic, and imaging-based technologies. Collaborations with pharmaceutical firms for companion diagnostics and personalized treatment regimens are key strategic moves. In addition, companies are expanding their geographic presence through partnerships with local healthcare providers and governments to address the rising demand for cancer diagnostics across emerging markets.

Key Companies Profiled:

  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories
  • Illumina Inc.
  • bioMerieux SA
  • Qiagen
  • Siemens Healthineers
  • GE Healthcare
  • Hologic Inc.
  • Koninklijke Philips N.V. (Philips)
  • Agilent Technologies Inc.
  • Becton, Dickinson and Company (BD)
  • Myriad Genetics Inc.
  • AstraZeneca
  • Regeneron
  • Novartis
  • Bio-Rad Laboratories
  • Cancer Diagnostics Inc.
  • Quidel Corporation
  • Others

Market Segmentation

By Diagnostic Test

  • Biomarker Test
  • Prostate-Specific Antigen (PSA)
  • Circulating Tumor Cells (CTC)
  • Alpha-Fetoprotein (AFP)
  • Cancer Antigen 125 (CA-125)
  • HER2
  • Other
  • Imaging Technology
  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT)
  • Positron Emission Tomography (PET)
  • Mammography
  • Others
  • Endoscopy
  • Colonoscopy
  • Biopsy
  • Others

By Application

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma Cancer
  • Blood Cancer
  • Ovarian Cancer
  • Other

By End-Use

  • Hospitals
  • Diagnostic Laboratories
  • Cancer Research Institutes
  • Ambulatory Surgical Centers

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Cancer Diagnostics Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. COVID-19 Impact Analysis
  • 2.4. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Value Chain Analysis
  • 3.2. Diagnostic Test Adoption / Usage Analysis
  • 3.3. Prevalence & Incidence of Cancer
  • 3.4. Government Initiatives & Funding in Cancer Diagnostics
  • 3.5. Key Market Players
  • 3.6. Regulatory Landscape
  • 3.7. PESTLE Analysis
  • 3.8. Porter's Five Force Analysis
  • 3.9. Consumer Behavior Analysis

4. Global Cancer Diagnostics Market Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Cancer Diagnostics Market Outlook Diagnostic Test
    • 4.3.1. Historical Market Size (US$ Bn) Analysis, By Diagnostic Test, 2019-2024
    • 4.3.2. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
      • 4.3.2.1. Biomarker Test
        • 4.3.2.1.1. Prostate-Specific Antigen (PSA)
        • 4.3.2.1.2. Circulating Tumor Cells (CTC)
        • 4.3.2.1.3. Alpha-Fetoprotein (AFP)
        • 4.3.2.1.4. Cancer Antigen 125 (CA-125)
        • 4.3.2.1.5. HER2
        • 4.3.2.1.6. Other
      • 4.3.2.2. Imaging Technology
        • 4.3.2.2.1. Magnetic Resonance Imaging (MRI)
        • 4.3.2.2.2. Computed Tomography (CT)
        • 4.3.2.2.3. Positron Emission Tomography (PET)
        • 4.3.2.2.4. Mammography
        • 4.3.2.2.5. Others
      • 4.3.2.3. Endoscopy
      • 4.3.2.4. Colonoscopy
      • 4.3.2.5. Biopsy
      • 4.3.2.6. Others
    • 4.3.3. Market Attractiveness Analysis: Diagnostic Test
  • 4.4. Global Cancer Diagnostics Market Outlook Form
    • 4.4.1. Historical Market Size (US$ Bn) Analysis, By Form, 2019-2024
    • 4.4.2. Current Market Size (US$ Bn) Analysis and Forecast, By Form, 2025-2032
      • 4.4.2.1. Isolates
      • 4.4.2.2. Concentrates
      • 4.4.2.3. Hydrolysates
    • 4.4.3. Market Attractiveness Analysis: Form
  • 4.5. Global Cancer Diagnostics Market Outlook Application
    • 4.5.1. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2024
    • 4.5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
      • 4.5.2.1. Lung Cancer
      • 4.5.2.2. Breast Cancer
      • 4.5.2.3. Prostate Cancer
      • 4.5.2.4. Colorectal Cancer
      • 4.5.2.5. Melanoma Cancer
      • 4.5.2.6. Blood Cancer
      • 4.5.2.7. Ovarian Cancer
      • 4.5.2.8. Other
    • 4.5.3. Market Attractiveness Analysis: Application
  • 4.6. Global Cancer Diagnostics Market Outlook End-use
    • 4.6.1. Historical Market Size (US$ Bn) Analysis, By End-use, 2019-2024
    • 4.6.2. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
      • 4.6.2.1. Hospitals
      • 4.6.2.2. Diagnostic Laboratories
      • 4.6.2.3. Cancer Research Institutes
      • 4.6.2.4. Ambulatory Surgical Centers
    • 4.6.3. Market Attractiveness Analysis: End-use

5. Global Cancer Diagnostics Market Outlook Region

  • 5.1. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.2.1. North America
    • 5.2.2. Latin America
    • 5.2.3. Europe
    • 5.2.4. East Asia
    • 5.2.5. South Asia and Oceania
    • 5.2.6. Middle East & Africa
  • 5.3. Market Attractiveness Analysis: Region

6. North America Cancer Diagnostics Market Outlook

  • 6.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.1.1. By Country
    • 6.1.2. By Diagnostic Test
    • 6.1.3. By Application
    • 6.1.4. By End-use
  • 6.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.2.1. U.S.
    • 6.2.2. Canada
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
    • 6.3.1. Biomarker Test
      • 6.3.1.1. Prostate-Specific Antigen (PSA)
      • 6.3.1.2. Circulating Tumor Cells (CTC)
      • 6.3.1.3. Alpha-Fetoprotein (AFP)
      • 6.3.1.4. Cancer Antigen 125 (CA-125)
      • 6.3.1.5. HER2
      • 6.3.1.6. Other
    • 6.3.2. Imaging Technology
      • 6.3.2.1. Magnetic Resonance Imaging (MRI)
      • 6.3.2.2. Computed Tomography (CT)
      • 6.3.2.3. Positron Emission Tomography (PET)
      • 6.3.2.4. Mammography
      • 6.3.2.5. Others
    • 6.3.3. Endoscopy
    • 6.3.4. Colonoscopy
    • 6.3.5. Biopsy
    • 6.3.6. Others
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 6.4.1. Lung Cancer
    • 6.4.2. Breast Cancer
    • 6.4.3. Prostate Cancer
    • 6.4.4. Colorectal Cancer
    • 6.4.5. Melanoma Cancer
    • 6.4.6. Blood Cancer
    • 6.4.7. Ovarian Cancer
    • 6.4.8. Other
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 6.5.1. Hospitals
    • 6.5.2. Diagnostic Laboratories
    • 6.5.3. Cancer Research Institutes
    • 6.5.4. Ambulatory Surgical Centers
  • 6.6. Market Attractiveness Analysis

7. Europe Cancer Diagnostics Market Outlook

  • 7.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.1.1. By Country
    • 7.1.2. By Diagnostic Test
    • 7.1.3. By Form
    • 7.1.4. By Application
    • 7.1.5. By End-use
  • 7.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.2.1. Germany
    • 7.2.2. France
    • 7.2.3. U.K.
    • 7.2.4. Italy
    • 7.2.5. Spain
    • 7.2.6. Russia
    • 7.2.7. Rest of Europe
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
    • 7.3.1. Biomarker Test
      • 7.3.1.1. Prostate-Specific Antigen (PSA)
      • 7.3.1.2. Circulating Tumor Cells (CTC)
      • 7.3.1.3. Alpha-Fetoprotein (AFP)
      • 7.3.1.4. Cancer Antigen 125 (CA-125)
      • 7.3.1.5. HER2
      • 7.3.1.6. Other
    • 7.3.2. Imaging Technology
      • 7.3.2.1. Magnetic Resonance Imaging (MRI)
      • 7.3.2.2. Computed Tomography (CT)
      • 7.3.2.3. Positron Emission Tomography (PET)
      • 7.3.2.4. Mammography
      • 7.3.2.5. Others
    • 7.3.3. Endoscopy
    • 7.3.4. Colonoscopy
    • 7.3.5. Biopsy
    • 7.3.6. Others
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 7.4.1. Lung Cancer
    • 7.4.2. Breast Cancer
    • 7.4.3. Prostate Cancer
    • 7.4.4. Colorectal Cancer
    • 7.4.5. Melanoma Cancer
    • 7.4.6. Blood Cancer
    • 7.4.7. Ovarian Cancer
    • 7.4.8. Other
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 7.5.1. Hospitals
    • 7.5.2. Diagnostic Laboratories
    • 7.5.3. Cancer Research Institutes
    • 7.5.4. Ambulatory Surgical Centers
  • 7.6. Market Attractiveness Analysis

8. East Asia Cancer Diagnostics Market Outlook

  • 8.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.1.1. By Country
    • 8.1.2. By Diagnostic Test
    • 8.1.3. By Application
    • 8.1.4. By End-use
  • 8.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.2.1. China
    • 8.2.2. Japan
    • 8.2.3. South Korea
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
    • 8.3.1. Biomarker Test
      • 8.3.1.1. Prostate-Specific Antigen (PSA)
      • 8.3.1.2. Circulating Tumor Cells (CTC)
      • 8.3.1.3. Alpha-Fetoprotein (AFP)
      • 8.3.1.4. Cancer Antigen 125 (CA-125)
      • 8.3.1.5. HER2
      • 8.3.1.6. Other
    • 8.3.2. Imaging Technology
      • 8.3.2.1. Magnetic Resonance Imaging (MRI)
      • 8.3.2.2. Computed Tomography (CT)
      • 8.3.2.3. Positron Emission Tomography (PET)
      • 8.3.2.4. Mammography
      • 8.3.2.5. Others
    • 8.3.3. Endoscopy
    • 8.3.4. Colonoscopy
    • 8.3.5. Biopsy
    • 8.3.6. Others
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 8.4.1. Lung Cancer
    • 8.4.2. Breast Cancer
    • 8.4.3. Prostate Cancer
    • 8.4.4. Colorectal Cancer
    • 8.4.5. Melanoma Cancer
    • 8.4.6. Blood Cancer
    • 8.4.7. Ovarian Cancer
    • 8.4.8. Other
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 8.5.1. Hospitals
    • 8.5.2. Diagnostic Laboratories
    • 8.5.3. Cancer Research Institutes
    • 8.5.4. Ambulatory Surgical Centers
  • 8.6. Market Attractiveness Analysis

9. South Asia & Oceania Cancer Diagnostics Market Outlook

  • 9.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.1.1. By Country
    • 9.1.2. By Diagnostic Test
    • 9.1.3. By Application
    • 9.1.4. By End-use
  • 9.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.2.1. India
    • 9.2.2. Indonesia
    • 9.2.3. Thailand
    • 9.2.4. Singapore
    • 9.2.5. ANZ
    • 9.2.6. Rest of South Asia & Oceania
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
    • 9.3.1. Biomarker Test
      • 9.3.1.1. Prostate-Specific Antigen (PSA)
      • 9.3.1.2. Circulating Tumor Cells (CTC)
      • 9.3.1.3. Alpha-Fetoprotein (AFP)
      • 9.3.1.4. Cancer Antigen 125 (CA-125)
      • 9.3.1.5. HER2
      • 9.3.1.6. Other
    • 9.3.2. Imaging Technology
      • 9.3.2.1. Magnetic Resonance Imaging (MRI)
      • 9.3.2.2. Computed Tomography (CT)
      • 9.3.2.3. Positron Emission Tomography (PET)
      • 9.3.2.4. Mammography
      • 9.3.2.5. Others
    • 9.3.3. Endoscopy
    • 9.3.4. Colonoscopy
    • 9.3.5. Biopsy
    • 9.3.6. Others
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 9.4.1. Lung Cancer
    • 9.4.2. Breast Cancer
    • 9.4.3. Prostate Cancer
    • 9.4.4. Colorectal Cancer
    • 9.4.5. Melanoma Cancer
    • 9.4.6. Blood Cancer
    • 9.4.7. Ovarian Cancer
    • 9.4.8. Other
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 9.5.1. Hospitals
    • 9.5.2. Diagnostic Laboratories
    • 9.5.3. Cancer Research Institutes
    • 9.5.4. Ambulatory Surgical Centers
  • 9.6. Market Attractiveness Analysis

10. Latin America Cancer Diagnostics Market Outlook

  • 10.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.1.1. By Country
    • 10.1.2. By Diagnostic Test
    • 10.1.3. By Application
    • 10.1.4. By End-use
  • 10.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.2.1. Brazil
    • 10.2.2. Mexico
    • 10.2.3. Rest of Latin America
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
    • 10.3.1. Biomarker Test
      • 10.3.1.1. Prostate-Specific Antigen (PSA)
      • 10.3.1.2. Circulating Tumor Cells (CTC)
      • 10.3.1.3. Alpha-Fetoprotein (AFP)
      • 10.3.1.4. Cancer Antigen 125 (CA-125)
      • 10.3.1.5. HER2
      • 10.3.1.6. Other
    • 10.3.2. Imaging Technology
      • 10.3.2.1. Magnetic Resonance Imaging (MRI)
      • 10.3.2.2. Computed Tomography (CT)
      • 10.3.2.3. Positron Emission Tomography (PET)
      • 10.3.2.4. Mammography
      • 10.3.2.5. Others
    • 10.3.3. Endoscopy
    • 10.3.4. Colonoscopy
    • 10.3.5. Biopsy
    • 10.3.6. Others
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 10.4.1. Lung Cancer
    • 10.4.2. Breast Cancer
    • 10.4.3. Prostate Cancer
    • 10.4.4. Colorectal Cancer
    • 10.4.5. Melanoma Cancer
    • 10.4.6. Blood Cancer
    • 10.4.7. Ovarian Cancer
    • 10.4.8. Other
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 10.5.1. Hospitals
    • 10.5.2. Diagnostic Laboratories
    • 10.5.3. Cancer Research Institutes
    • 10.5.4. Ambulatory Surgical Centers
  • 10.6. Market Attractiveness Analysis

11. Middle East & Africa Cancer Diagnostics Market Outlook

  • 11.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.1.1. By Country
    • 11.1.2. By Diagnostic Test
    • 11.1.3. By Application
    • 11.1.4. By End-use
  • 11.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.2.1. GCC Countries
    • 11.2.2. Egypt
    • 11.2.3. South Africa
    • 11.2.4. Northern Africa
    • 11.2.5. Rest of Middle East & Africa
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
    • 11.3.1. Biomarker Test
      • 11.3.1.1. Prostate-Specific Antigen (PSA)
      • 11.3.1.2. Circulating Tumor Cells (CTC)
      • 11.3.1.3. Alpha-Fetoprotein (AFP)
      • 11.3.1.4. Cancer Antigen 125 (CA-125)
      • 11.3.1.5. HER2
      • 11.3.1.6. Other
    • 11.3.2. Imaging Technology
      • 11.3.2.1. Magnetic Resonance Imaging (MRI)
      • 11.3.2.2. Computed Tomography (CT)
      • 11.3.2.3. Positron Emission Tomography (PET)
      • 11.3.2.4. Mammography
      • 11.3.2.5. Others
    • 11.3.3. Endoscopy
    • 11.3.4. Colonoscopy
    • 11.3.5. Biopsy
    • 11.3.6. Others
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 11.4.1. Lung Cancer
    • 11.4.2. Breast Cancer
    • 11.4.3. Prostate Cancer
    • 11.4.4. Colorectal Cancer
    • 11.4.5. Melanoma Cancer
    • 11.4.6. Blood Cancer
    • 11.4.7. Ovarian Cancer
    • 11.4.8. Other
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 11.5.1. Hospitals
    • 11.5.2. Diagnostic Laboratories
    • 11.5.3. Cancer Research Institutes
    • 11.5.4. Ambulatory Surgical Centers
  • 11.6. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping by Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. F. Hoffmann-La Roche Ltd
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Sources
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Thermo Fisher Scientific Inc.
    • 12.3.3. Abbott Laboratories
    • 12.3.4. Illumina Inc.
    • 12.3.5. bioMerieux SA
    • 12.3.6. Qiagen
    • 12.3.7. Siemens Healthineers
    • 12.3.8. GE Healthcare
    • 12.3.9. Hologic Inc.
    • 12.3.10. Agilent Technologies Inc.
    • 12.3.11. Becton, Dickinson and Company (BD)
    • 12.3.12. Myriad Genetics Inc.
    • 12.3.13. AstraZeneca
    • 12.3.14. Regeneron
    • 12.3.15. Novartis
    • 12.3.16. BIO-RAD LABORATORIES
    • 12.3.17. CANCER DIAGNOSTICS INC.
    • 12.3.18. QUIDEL CORPORATION
    • 12.3.19. Koninklijke Philips N.V. (Philips)
    • 12.3.20. Others

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations